MD MBA - Reunion Neuroscience VP Director

REUNDelisted Stock  USD 1.12  0.01  0.90%   

Insider

MD MBA is VP Director of Reunion Neuroscience
Webhttps://www.fieldtriphealth.com

Reunion Neuroscience Management Efficiency

The company has return on total asset (ROA) of (0.2651) % which means that it has lost $0.2651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8635) %, meaning that it created substantial loss on money invested by shareholders. Reunion Neuroscience's management efficiency ratios could be used to measure how well Reunion Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities.
Reunion Neuroscience currently holds 3.37 M in liabilities. Reunion Neuroscience has a current ratio of 46.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reunion Neuroscience's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

John SchoellermanOxford Nanopore Technologies
N/A
Stephen ToorPharming Group NV
52
Richard ComptonOxford Nanopore Technologies
N/A
Christopher MDNuvalent
55
Ruud OutersterpPharming Group NV
59
Craig EsqCingulate
51
Deborah KnobelmanSenti Biosciences
50
Philip LeeSenti Biosciences
42
Susanne EmbletonPharming Group NV
N/A
James CollinsSenti Biosciences
58
Anurag RelanPharming Group NV
51
Gordon SangheraOxford Nanopore Technologies
N/A
Darlene NociNuvalent
46
Wendy BlosserAccustem Sciences
57
Sara LeOxford Nanopore Technologies
N/A
Susan KahlertSenti Biosciences
N/A
Mireille MScPharming Group NV
55
Rajkumar PatilOKYO Pharma Ltd
65
Jeroen WakkermanPharming Group NV
54
Joe FlanaganAccustem Sciences
49
MBA MDPharming Group NV
63
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. Reunion Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 194 people. Reunion Neuroscience (REUN) is traded on NASDAQ Exchange in USA and employs 16 people.

Management Performance

Reunion Neuroscience Leadership Team

Elected by the shareholders, the Reunion Neuroscience's board of directors comprises two types of representatives: Reunion Neuroscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reunion. The board's role is to monitor Reunion Neuroscience's management team and ensure that shareholders' interests are well served. Reunion Neuroscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reunion Neuroscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, VP Director
Nathan BSc, Chief Officer
Stephan Cote, Head Quality
Hannan Fleiman, CoFounder Director
Mujeeb Jafferi, COFounder COO
Edward CPA, Chief Officer
Vicki Reed, Chief Officer
Curtis Weber, Gen Sec
JD Esq, CEO Pres
Matt Emmer, Director Devel

Reunion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reunion Neuroscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Reunion Neuroscience

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Reunion Neuroscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reunion Neuroscience will appreciate offsetting losses from the drop in the long position's value.

Moving against Reunion Stock

  0.86CSLLY CSLPairCorr
  0.83REGN Regeneron PharmaceuticalsPairCorr
  0.82CMXHF CSL LimitedPairCorr
  0.71QSAM Qsam BiosciencesPairCorr
  0.7NVO Novo Nordisk ASPairCorr
The ability to find closely correlated positions to Reunion Neuroscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Reunion Neuroscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Reunion Neuroscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Reunion Neuroscience to buy it.
The correlation of Reunion Neuroscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Reunion Neuroscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Reunion Neuroscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Reunion Neuroscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Reunion Stock

If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing